SCHEMBL6800199

SCHEMBL6800199

Cc1ccc(-c2ccccc2C(=O)Nc2ccc3c(c2)CCN3C(=O)Cc2csc(NC=O)n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
ALDH1A1 P00352 2/20 0.44
TP53 P04637 2/20 0.43
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
KLK7 P49862 1/20 0.42
POLB P06746 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
AVPR2 P30518 6/20 0.40
CASP3 P42574 1/20 0.40
CASP2 P42575 1/20 0.40
LMNA P02545 1/20 0.40
CREBBP Q92793 1/20 0.40
AVPR1A P37288 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6803496 0.93 SLC12A2 (0.44) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6801575 0.92 MAPT (0.53) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6801577 0.92 MAPT (0.43) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6800495 0.91 MTTP (0.47) MAPTALDH1A1TP53LMNA
SCHEMBL6804824 0.90 CASP3 (0.49) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6798990 0.90 MAPT (0.43) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6803455 0.89 MAPT (0.44) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6670037 0.85 AVPR2 (0.43) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6669291 0.84 MAPT (0.48) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6668952 0.84 LMNA (0.41) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157866-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157866-A1 Amide compounds APOB, NR1H2, NR1H3 MAPT 4047/4885NPC1 40/4885RAB9A 4004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.